Skip To Main Content

Dyslipidemi

Sort by
Lipid management in patients with diabetes mellitus

Lipid management in patients with diabetes mellitus

Key principles of lipid management (LDL-C in particular) in accordance with the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, and the 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.

Acute LDL-C reduction post ACS: Strike early and strike strong: From evidence to clinical practice

Acute LDL-C reduction post ACS: Strike early and strike strong: From evidence to clinical practice

A clinical consensus statement of Association for acute cardiovascular care (ACVC), in collaboration with European association of preventive cardiology (EAPC) and the European Society of Cardiology working group on cardiovascular Pharmacotherapy Krychtiuk KA, et al. Eur Heart J Acute Cardiovasc Care. 2022;11(12):939–949.

Approach for patients with coronary artery disease (CAD): focus on LDL-C control

Approach for patients with coronary artery disease (CAD): focus on LDL-C control

Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Cardiovascular diseases (CVDs) are the leading cause of death globally<sup>1</sup>

Cardiovascular diseases (CVDs) are the leading cause of death globally

Why choose PRALUENT<sup>®</sup>?

Why choose PRALUENT®?

The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.2

What is PRALUENT<sup>®</sup>(alirocumab)?

What is PRALUENT®(alirocumab)?

PRALUENT®: a PCSK9i that ticks all the boxes1–4

 

PRALUENT is a PCSK9i that reduces the levels of LDL-C in the blood.2 It is a fully human IgG1 monoclonal antibody that works by inhibiting the binding of PCSK9 to LDL- receptors. As a result, PRALUENT increases the number of LDL-receptors available to clear LDL, thereby lowering LDL-C levels.2 Elevated LDL-C levels have been significantly associated with cardiovascular disease such as heart attacks and strokes.1

PRALUENT is available as a only,<sup>¥</sup> once-monthly pen

PRALUENT is available as a unique,¥ once-monthly pen

146 for Lipid Management After ACS

146 for Lipid Management After ACS

2024 ESC Guidelines for the management of chronic coronary syndromes

2024 ESC Guidelines for the management of chronic coronary syndromes

Felicita Andreotti, Italy; Christiaan J M Vrints, Belgium

Referenser

Referenser

Biverkningar

Biverkningar